Myocardial ischemia occurs when there is a supply and demand imbalance between the delivery of oxygenated blood to the myocardium and the needs of the myocardium to maintain normal cardiac function at any level of activity. The commonest cause of the imbalance is obstructive coronary artery disease. A pharmacologic hemodynamic approach to therapy principally focuses on reducing demand (slowing heart rate, lowering blood pressure, reducing contractility and increasing peripheral venous and arterial vasodilatation), with a variable effect on supply (coronary vasodilatation). This is a proven and highly effective approach indirectly improving myocardial metabolism. An alternative and complementary strategy avoids any effect on hemodynamics, but by direct action at the cellular level minimizes the ischemic disruption of cardiac metabolism. Trimetazidine inhibits the fatty acid oxidation enzyme long-chain 3-ketoacyl-coenzyme A thiolase (3-KAT), thereby decreasing fatty acid oxidation and increasing the combustion of glucose and lactate. This switch back from ischemia-induced fatty acid oxidation to glucose oxidation has been shown to be of significant clinical benefit, both subjectively and objectively, independent of or in combination with conventional hemodynamic agents.